Quadrant Biosciences Inc Email Format

Biotechnology ResearchUnited States51-200 Employees

Quadrant Biosciences is a United States–based biotechnology research company focused on epigenetic diagnostics and the early detection of neurological disorders and other major health issues. Its Clarifi platform aims to reveal epigenetic signatures associated with conditions such as autism spectrum disorder, Parkinson’s disease, and mild traumatic brain injury, supporting clinicians in diagnosis and treatment decisions.

In March 2020, the company redirected some resources to support the COVID-19 response, leveraging its RNA-analysis capabilities on several projects. The Clarifi COVID-19 Test Kit received FDA Emergency Use Authorization in September 2020 for SARS-CoV-2 diagnosis. In March 2023, Quadrant Biosciences announced Clarifi ASD, described as the first epigenetic test for autism spectrum disorder. In November 2023, the company's CEO was honored with the SUNY Upstate Medical University's President's Award for Distinguished Service.

Sign up for free to view info

Company overview Employee directory